Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Broad Spectrum Anti-viral Agenti_ImmuneMed Inc
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Development of broad spectrum anti-viral agent using body-derived virus suppressing factor, activati...
Contact
Participants
You
Email me a copy of this message

Key Technology Highlights


 


Antiviral drug, VSF (virus suppressing factor)


1. Broad spectrum effect on various viruses by affecting host cell


2. Due to the potent anti-viral effects of VSF, only 1 hour is fully enough to get potent


anti-viral effects compare to over 12 hours required for interferon activity.


3.VSF shows the potent inhibitory effect of viral replication both in vitro and in vivo.


4.Unlike interferon, Inhibition of MHC-I & -II induction and macrophages, CD4 and CD8 T cell infiltration


5. No side effects and drug resistant found


 



















Interferon




VSF




 




•      Broad spectrum to several viruses by cellular stimulation




•      Broad spectrum to several viruses by cellular stimulation




•      Induction of excessive infiltration of immune cell




•      Side effects with high dosage




•      Limited spectrum




•      Low activity in vivo




 




•      Inhibition of infiltration of immune cell




•      No side effect




•      Broad spectrum




•      Highly effective both in vitro and in vivo




•      Rapid effectiveness




 



 


 


 


 


 


 


 


 


Technology Overview


 


1.    Technology platform


1)    History of VSF identification


 


  2) The inhibitory effect of immune cell infiltration and viral replication


(1) Influenza virus


When influenza virus is infected, it causes pneumonia and immune cell infiltration in alveolar rapidly. However, the administration of VSF during infection has clearly shown the inhibition of excessive inflammation and the recovery of disease from the mouse experiment.


 


(2) Hepatitis virus


If hepatitis virus is infected, it causes the degeneration of hepatocyte and immune cell infiltration to hepatic parenchymal tissue.


However, the treatment of VSF during viral infection has clearly shown the inhibition of hepatic degeneration and inflammation and the recovery of health in animal model system.


 


(3) EMC virus causing Diabetes



When virus is infected to the ß cell of pancreatic islet


 


      The destruction of ß cell         Confirming the viral replication


       of pancreatic islet by immune     in the destructed pancreatic islet


 cell infiltration


 



When virus is infected to the ß cell of pancreatic islet and treated with VSF


 


No immune cell infiltration         Confirming the viral protein


found in the islet                 in the healthy looking islet.


                                       After 1 week post-infection,


            viral proteins disappear.


 


2. Stage of development


Currently, not only viral clearance of pathogenic viruses such as, Hepatitis, Herpes and Influenza virus but also the inhibition of hyper-inflammatory response have been confirmed through various in vitro and in vivo experiments.


 


By registering some results, ImmuneMed Inc. acquired US patent (No.7514082). Eventually, we succeeded in producing chimeric humanized VSF(chVSF) and then are developing humanized VSF(hVSF) for using this chVSF as a novel antiviral drug.


 


The most recent progress in VSF development is that we identified about 60KD receptor called p60


under investigation to characterize. This VSF receptor, p60 is not present on the normal cell but is


only expressed on the infected cell surface after viral infection.


 


Now ImmuneMed Inc. has plans to submit pre-clinic and clinical test for Hepatitis B, Hepatitis C and Influenza after setting up for the appropriation and mass production of chVSF.

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE